ORI found that falsified and/or fabricated data were included in the following one (1) funded NIH grant, two (2) publications, two (2) posters, and one (1) Specifically, Respondent falsified and/or fabricated data in the following:
• R01 HL107949-01 for: D Figure 1B for Western blots of asmooth muscle actin (a-SMA), Vimentin, Collagen I and Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) expression in human cardiac fibroblasts isolated from failing left ventricles (HF) and non-failing heart controls (CF) D Figure 2A for Western blots of G protein-coupled receptor kinase-2 (GRK2) and GAPDH expression in HF and CF, and the related densitometric analysis • JBC 2011 for: D Figure 1A for a Western blot of Vimentin expression in HF and CF, and the related densitometric analysis D Figures 1D and 2D for Western blots of GAPDH expression in HF and CF, and the related densitometric analyses • JBC 2010 for: D Figure 7A for Western blots of phosphorylated Rhodopsin (Rho) and GRK2 expression in non-transgenic (NTG) (lanes 1-4) and Protein Kinase Ca cardiac-specific activation (PKCaAC) transgenic (lanes 5-6) mice, and Figure 7B for the related densitometric analysis • GC2006, Figure 7 , HP2010, Figure 5 , and CR2009, Slide 15 for: D Western blots of phosphorylated Rho and GRK2 expression in NTG and PKCaAC transgenic mice, and the related densitometric analysis • HP2010 for: D Figure 5 for a Western blot of GRK2 expression in NTG and PKCaAC transgenic mice, and the related densitometric analysis Dr. D'Souza has entered into a Voluntary Settlement Agreement with ORI, in which she voluntarily agreed to the administrative actions set forth below:
(1) Respondent agreed that for two (2) years beginning on May 6, 2016, any institution employing her shall submit in conjunction with each application for U.S. Public Health Service (PHS) funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a supervision plan to ORI. Respondent agreed that prior to the submission of an application for PHS support for a research project on which the Respondent's participation is proposed and prior to Respondent's participation in any capacity on PHS-supported research, any institution employing her shall ensure that a plan for supervision of her duties is submitted to ORI for approval. The supervision plan must be designed to ensure the scientific integrity of Respondent's PHSsupported research contribution and include the specific elements as outlined below. Respondent agreed that she shall not participate in any PHSsupported research until such a supervision plan is submitted to and approved by ORI. Respondent agreed to maintain responsibility for compliance with the agreed upon supervision plan.
(2) The requirements for Respondent's supervision plan are as follows:
i. A committee of senior faculty members and officials at the institution who are familiar with Respondent's field of research, but not including Respondent's supervisor or collaborators, will provide oversight and guidance for two (2) years beginning on May 6, 2016. The committee will review PHS-supported primary data from Respondent and submit a report to ORI at six (6) month intervals, setting forth the committee meeting dates, Respondent's compliance with appropriate research standards, and confirming the integrity of Respondent's PHS-supported research.
ii. The committee will conduct an advance review of any PHS grant application (including supplements, resubmissions, etc.), manuscripts reporting PHS-funded research submitted for publication, and abstracts. The review will include a discussion with Respondent of the primary data represented in those documents and will include a certification that the data presented in the proposed application/ publication is supported by the research record.
(3) Respondent agreed that for two (2) years beginning on May 6, 2016, any institution employing her shall submit, in conjunction with each application for PHS funds, or report, manuscript, or abstract involving PHS-supported research in which Respondent is involved, a certification to ORI at that the data provided by Respondent are based on actual experiments or are otherwise legitimately derived and that the data, procedures, and methodology are accurately reported in the application, report, manuscript, or abstract.
(4) Respondent agreed to exclude herself voluntarily from serving in any advisory capacity to PHS including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of two (2) years, beginning on May 6, 2016. The on-site meetings in Aberdeen and Rapid City, South Dakota will be conducted at the addresses noted below. Written comments must be received on or before September 1, 2016 at the address below.
Conference Call Information: 1-800-369-1747; Pass Code: 1381519.
ADDRESSES:
The meetings will be held at The Dakota Event Center located at 720 Lamont Street, Aberdeen, South Dakota; and at the Rushmore Plaza Holiday Inn Convention Center located at 505 N. Fifth Street, Rapid City, SD 57701, during the 13th Annual Direct Service Tribes National Meeting.
